News
Zacks Investment Research on MSN2d
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 ViewBioMarin Pharmaceutical BMRN reported second-quarter 2025 adjusted earnings per share (EPS) of $1.44, which beat the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback